Pulse cyclophosphamide showed no clear difference in adverse events ‐ treatment failure compared with continuous cyclophosphamide (low certainty).
Pulse cyclophosphamide showed no clear difference in serious infections compared with continuous cyclophosphamide (low certainty).
Rituximab showed no clear difference in death at 6 months compared with cyclophosphamide (moderate certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Rituximab showed no clear difference in remission at 6 months compared with cyclophosphamide (moderate certainty).
Rituximab showed no clear difference in relapse at 12 months compared with cyclophosphamide (low certainty).
Rituximab showed no clear difference in serious adverse events compared with cyclophosphamide (moderate certainty).
Rituximab showed no clear difference in serious Infections compared with cyclophosphamide (moderate certainty).
Mycophenolate mofetil showed no clear difference in death at 6 months compared with cyclophosphamide (low certainty).
The review found no eligible studies for this question.
Mycophenolate mofetil showed no clear difference in dialysis compared with cyclophosphamide (low certainty).
Mycophenolate mofetil showed no clear difference in relapse at any time point compared with cyclophosphamide (low certainty).
Mycophenolate mofetil probably leads to higher remission at 6 months compared with cyclophosphamide (moderate certainty).
Mycophenolate mofetil may leads to higher serious adverse events compared with cyclophosphamide (low certainty).
Mycophenolate mofetil showed no clear difference in infection compared with cyclophosphamide (moderate certainty).
Intravenous immunoglobulin showed no clear difference in death compared with placebo (low certainty).
The intervention may leads to lower dialysis at one year (low certainty).
The review found no eligible studies for this question.